Business Wire

Xceedance Secures Growth Investment from Portage Capital Solutions

14.10.2025 14:00:00 CEST | Business Wire | Press Release

Share

Xceedance, a global provider of technology-driven business solutions for the insurance industry, has received a growth investment from Portage Capital Solutions, a leading investor focused on the financial technology market, in exchange for a minority equity stake. With this investment, the total capital raised by the company, across equity and debt, now stands at approximately $100 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014802482/en/

Arun Balakrishnan, Group Chairman & CEO, Xceedance

This milestone marks the company’s first institutional equity financing since its founding in 2013, underscoring its position as one of the most disruptive players in the insurance services sector. The capital will be used to fuel Xceedance’s expanding portfolio of AI-enabled solutions and fund the accretive acquisition of insurance-focused service providers.

“Since inception, Xceedance has enjoyed exceptional, bootstrapped growth, scaling rapidly through profit reinvestment and the prudent use of debt. This investment not only strengthens our capital base but also connects us to Portage’s exceptional ecosystem in the insurance, technology and broader financial services markets, unlocking meaningful synergies that will help accelerate our growth,” said Arun Balakrishnan, Founder and CEO of Xceedance. “In Portage, we have found an investor aligned with our long-term vision, cultural values, and commitment to innovation.”

Xceedance was founded with the core belief that domain-focused business service providers are uniquely positioned to harness the transformative potential of generative AI, driven by a deep operational insight and understanding of complex insurance ecosystems. With more than 350 insurance clients globally and over 1,000 complex P&C workflows serviced across the insurance value chain, Xceedance exemplifies how technology-enabled delivery and extensive domain expertise can transform insurance operations. Through the development of its TPA platform, bolstered by the acquisition of Millenium Information Services and CIS Claim Services, Xceedance has continued to enhance its suite of offerings and strengthen its position globally.

“Xceedance has established itself as a best-in-class partner to both small, innovative insurers as well as some of the largest, most trusted names in the industry. With the rapid adoption of digital solutions across the market, Xceedance is poised for continued growth and expanded opportunities as a recognized thought leader to its clients and partners,” said Dan Ballen, General Partner & Co-Head of Portage Capital Solutions. “We’re thrilled to be partnering with Arun and the full Xceedance team on the next stage of their growth and look forward to helping them execute on their ambitious long-term vision.”

Morgan Partners, Ernst & Young, and Norton Rose Fulbright served as the exclusive advisors to Xceedance, while Portage was advised by Paul Hastings and RSM.

About Xceedance

Xceedance provides business solutions to the global insurance industry, enabled by technology platforms, advanced data and analytics, and the transformation of operating models through AI and deep domain expertise. With 5,500+ team members across the Americas, EMEA, and APAC, our technology-enabled delivery model blends insurance domain knowledge with next-generation technologies to deliver localized solutions and digital-first platforms. We empower 350+ diverse clients—including commercial, personal, and specialty lines re/insurers, mutuals, program administrators, brokers and agents, and Lloyd’s of London entities—to optimize non-distribution and non-capital functions, navigate market challenges, and accelerate profitable growth.

For more information, visit www.xceedance.com.

About Portage

Portage is a global investment platform focused on the fintech and financial services sectors with over US$4.7B under management, 115 portfolio companies, and 25 investment professionals. The firm has offices across North America, Europe, and the Middle East.

Portage partners with ambitious companies across all stages through its flagship Portage Ventures and Portage Capital Solutions fund strategies. The firm provides flexible capital and value-added partnership through the delivery of its global network of investors, commercial partners, advisors, and value creation experts. Portage’s dedicated value creation team provides portfolio companies with hands-on support across a wide range of functions, including go-to-market, tech & cyber, AI, mergers and acquisitions, and commercial partnerships to accelerate their paths to success. With deep industry knowledge and entrepreneurial experience, Portage is committed to supporting the leaders who are reshaping financial services.

Portage is a platform within Sagard, a global multi-strategy alternative asset management firm with over US$44B under management.

For more information, visit www.portageinvest.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014802482/en/

Contacts

Media:
Candace Boyle
the10company
+1 610-256-1068
candace.boyle@the10company.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye